Sharma and Lippman join Alnylam C-suite
Plus Shah now COO at Precigen and updates from Carmot, Evozyne, Matinas, Maxwell and more
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) hired Piyush Sharma as chief ethics and compliance officer and Evan Lippman as chief corporate development and strategy officer, a newly created role. Sharma joins Alnylam from Alexion Pharmaceuticals Inc., where he was head of compliance. He also held various compliance positions at Pfizer Inc. (NYSE:PFE), including chief compliance counsel for the oncology and emerging markets business. Lippman was president and COO at Intima Bioscience Inc. and SVP, head of corporate development, M&A and valuation for Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK).
Cell and gene therapy company Precigen Inc. (NASDAQ:PGEN) hired Rutul Shah as COO, also a newly created role, effective Oct. 1. Shah joined Precigen in 2014 and has served in roles of increasing responsibility, most recently as head of operations and portfolio. ...